Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?
Plastaras
John P
JP
University of Pennsylvania School of Medicine, Department of Radiation Oncology, Philadelphia, Pennsylvania 19104, USA.
Cengel
Keith A
KA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000187:drug effects / Q000502:physiology*; D009363:Neoplasm Proteins / Q000187:drug effects / Q000502:physiology*; D010190:Pancreatic Neoplasms; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects / Q000502:physiology; D000077022:Survivin; D000093542:Gemcitabine
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D000077022:Survivin; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine